| PRIMARY INFORMATION |
|---|
| ID | 1618 |
| PMID | 25786877 |
| Year | 2013 |
| Sequence | ALA |
| Name | 5Aminolevulinic acid |
| Length | 3 |
| N-Terminal Modification | Free |
| C-Terminal Modification | Free |
| Linear/ Cyclic | Linear |
| Chirality | L |
| Chemical Modification | None |
| Origin of Peptide | intermediate in heme biosynthesis and is the precursor of protoporphyrin IX |
| Nature of Peptide/Cargo | ALA is used as an endogenous photosensitizer in photodynamic therapy for a range of non-melanoma skin cancers like basal cell carcinoma, squamouscell carcinoma, actinic keratoses and Bowen's disease, and inphoto diagnosi |
| Mechanism | Not mentioned |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | HPLC and liquid scintillation counting, |
| Enhancer | The donor solution pH was maintained at physiological pH 7.4 or at pH levels 6.0, 5.5, 5.0 and 3 using 0.1 or 0.01 M sodium hydroxide (NaOH) and/or 0.1 or 0.01 M hydrochloric acid (HCl) solutions. |
| Properties of enhancer | Not mentioned |
| Concentration | 1-10 mg/ml |
| Incubation time | Not mentioned |
| Tissue permeability (value with units) | electroosmotic volume flux was observed to study peptide penetration. |
| Tissue Sample | Human epidermal membrane |
| Ex vivo/In vivo/In vitro | in vitro |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N[C@@H](C)C(=O)N[C@@H]
(CC(C)C)C(=O)N[C@@H](C)CO |
